Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory in Treating COVID-19 Disease

Inclusion Criteria: * Patients tested positive (PCR) for SARS-CoV-2 and clinically symptomatic. * Adult patients with age \>18 years. * Patients willing and able to sign the study informed consent form. Exclusion Criteria: * Critically severe disease patients (having Respiratory failure requiring mechanical ventilation, or signs of septic shock or multiple organ failure requiring ICU admission). * Patients who are unconscious * Patients who have convulsions * Patients suffering from central cyanosis with SPO2\< 90% (for asthmatic patients with SPO2\<88%) * Pregnant or lactating women * Patients with a known history of pro-inflammatory diseases (patients with autoimmune diseases, patients receiving chemotherapy for cancer, patients with malabsorption, patients with inflammatory bowel disease, Crohn's disease or ulcerative colitis). * History or suspected immunosuppressive or immunodeficient state including HIV infection, or chronic immunosuppressant medication (more than 14 days) within the past 3 months (inhaled and topical steroids are allowed). * Patients with severe renal impairment (GFR \<60 ml/min/1.73m2 as measured by the Cockcroft-Gault formula). * Patient with severe hepatic impairment, biliary cirrhosis or cholestasis * Patients who received immunoregulatory therapy within one month before the start of the study. * Patients with Known or suspected allergy or any contraindications to Lactoferrin. * Any condition, according to the judgment of the investigator, would…